Basic Information
Ozurdex
Regulatory Information
EMEA/H/C/001140
July 26, 2010
May 20, 2010
20
July 2, 2024
Company Information
Germany
Knollstrasse 67061 Ludwigshafen
AbbVie Deutschland GmbH & Co. KG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO). Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis. Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Overview Summary
Ozurdex is an implant that is injected into the eye. It is used to treat adults with impaired vision due to macular oedema associated with: - blockage of the veins carrying blood from the back of the eye; - damage to blood vessels caused by diabetes in patients who have an artificial lens in their eye or in whom other treatment did not work or was unsuitable. Macular oedema is swelling in the macula, the central part of the retina (the light-sensing layer at the back of the eye), which can reduce the central part of a person’s vision and affect tasks such as reading and driving. Ozurdex is also used to treat adults with non-infectious uveitis at the back of the eye. Uveitis is inflammation of the uvea, the middle layer of the eye.